| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Burrows Scott L is a Chief Financial Officer at Spyre Therapeutics, Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $10.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $71.06 | $532,936.98 | -2.4% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 12,500 | $71.37 | $892,125.00 | -11.3% | - | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $49.34 | $370,076.00 | -3.7% | - | - | |
| Mar 3, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,500 | $40.65 | $101,620.00 | -1.3% | +83.6% | - | |
| Sep 2, 2025 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sell | 18,428 | $16.26 | $299,639.28 | -15.8% | +72.3% | - | |
| Sep 3, 2024 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sell | 18,531 | $28.17 | $522,073.86 | -13.7% | +3.9% | -36.8% | |
| Mar 6, 2023 | ARQT Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Sell | 291 | $15.26 | $4,441.65 | -0.5% | -41.1% | -25.0% | |
| Mar 2, 2023 | ARQT Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Sell | 1,850 | $15.90 | $29,421.25 | -1.6% | -52.5% | -25.6% | |
| Mar 7, 2022 | ARQT Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Sell | 303 | $16.85 | $5,104.17 | -0.4% | +24.5% | -17.1% | |
| Mar 1, 2022 | ARQT Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Sell | 420 | $17.75 | $7,456.13 | -1.9% | +19.3% | -4.6% |